Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis

Circulation

Volumn 108, Issue 9, 2003, Pages 1084-1088

  Schömig, Albert ^a   Ndrepepa, Gjin ^b   Mehilli, Julinda ^b   Schwaiger, Markus ^b   Schühlen, Helmut ^b   Nekolla, Stephan ^b   Pache, Jürgen ^b   Martinoff, Stefan ^b   Bollwein, Hildegard ^b   Kastrati, Adnan ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Myocardial infarction; Scintigraphy; Stents; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHRONOSEQUENCE; CLINICAL TRIAL; CORONARY STENT; FEMALE; FIBRINOLYTIC THERAPY; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

AGED; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RADIOPHARMACEUTICALS; STENTS; TECHNETIUM TC 99M SESTAMIBI; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 19244385186     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000086346.32856.9C     Document Type: Article

References (28)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
2. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093-2098.
3. Chesebro JH, Knatterud G, Roberts R, et al for Thrombolysis in Myocardial Infarction (TIMI) collaborators. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142-154.
4. Steg PG, Laperche T, Golmard JL, et al. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment: PERM Study Group. Prospective Evaluation of Reperfusion Markers. J Am Coll Cardiol. 1998;31:776-779.
5. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
6. Zeymer U, Tebbe U, Essen R, et al. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens: ALKK study group. Am Heart J. 1999;137:34-48.
7. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23:550-557.
8. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy: GUSTO-1 Investigators. J Am Coll Cardiol. 1996;27:1646-1655.
9. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283: 2941-2947.
10. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-444.
11. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation. 2000;101:101-108.
12. Schömig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000;343:385-391.
13. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet. 2002;359:920-925.
14. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
15. Karlson BW, Herlitz J, Edvardsson N, et al. Eligibility for intravenous thrombolysis in suspected acute myocardial infarction. Circulation. 1990; 82:1140-1146.
16. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ. 1996;312:1637-1641.
17. Kloner RA, Reimer KA, Jennings RB. Distribution of coronary collateral flow in acute myocardial ischaemic injury: effect of propranolol. Cardiovasc Res. 1976;10:81-90.
18. Clements IP, Christian TF, Higano ST, et al. Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation. 1993;88:1527-1533.
19. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992;327:1825-1831.
20. Schulz R, Rose J, Martin C, et al. Development of short-term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation. 1993;88:684-695.
21. Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol. 1998;31:1246-1251.
22. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999;100:14-20.
23. Simes RJ, Topol EJ, Holmes DR Jr, et al for GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation. 1995;91:1923-1928.
24. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983;71:368-376.
25. Huber K. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis. 2001;11:195-202.
26. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
27. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 1996;74:86-107.
28. Fukuyama T, Sobel BE, Roberts R. Microvascular deterioration: implications for reperfusion. Cardiovasc Res. 1984;18:310-320.